Hostname: page-component-5c6d5d7d68-thh2z Total loading time: 0 Render date: 2024-08-15T05:25:07.692Z Has data issue: false hasContentIssue false
  • English
  • Français

The Nrf2 inhibitor brusatol has a protective role in a rat model of oxygen-induced retinopathy of prematurity

Published online by Cambridge University Press:  17 March 2021

Xiuying Liang  and
Ruifen Wang
Xiuying Liang*
Affiliation:
Department of Neonatology, Cangzhou Central Hospital of Hebei Province, Cangzhou, Hebei, China
Ruifen Wang
Affiliation:
Department of Neonatology, Cangzhou Central Hospital of Hebei Province, Cangzhou, Hebei, China
*
*Address correspondence to: Xiuying Liang, E-mail: liangxiuying0608@sina.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Nuclear factor-erythroid 2-related factor 2 (Nrf2) has been testified to be involved in the development of retinopathy of prematurity (ROP), which can cause childhood visual impairment. Whether brusatol, an Nrf2 inhibitor, could be utilized to treat ROP was unknown. The oxygen-induced retinopathy rat model was established to mimic ROP, which was further intravitreal administrated with brusatol. Vessel morphology and microglial activation in the retina were assessed with histology analysis. The relative expression levels of angiogenesis and inflammation-related molecules were detected with Western blot and real-time polymerase chain reaction methods. Intravitreal brusatol administration could alleviate both angiogenesis and microgliosis induced by hyperoxia, along with down-regulation of vascular endothelial growth factor, vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, cluster of differentiation molecule 11B, tumor necrosis factor alpha, inducible nitric oxide synthase, glial fibrillary acidic protein, and IBA-1 expression. It was further revealed that Nrf2 and heme oxygenease-1 were diminished by brusatol administration. The results demonstrate the potential of intravitreal brusatol deliver to treat ROP with down-regulation of angiogenesis and microgliosis.

Keywords

Nrf2brusatoloxygen-induced retinopathyretinopathy of prematurity
Type
Research Article
Information
Visual Neuroscience , Volume 38 , 2021 , E002
Check for updates
Copyright
© The Author(s), 2021. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Agarwal, K. & Jalali, S. (2018). Classification of retinopathy of prematurity: From then till now. Community Eye Health 31, S4–S7.Google ScholarPubMed
Avignone, E., Lepleux, M., Angibaud, J. & Nagerl, U.V. (2015). Altered morphological dynamics of activated microglia after induction of status epilepticus. Journal of Neuroinflammation 12, 202.CrossRefGoogle ScholarPubMed
Bashinsky, A.L. (2017). Retinopathy of prematurity. North Carolina Medical Journal 78, 124–128.CrossRefGoogle ScholarPubMed
Bodeutsch, N. & Thanos, S. (2000). Migration of phagocytotic cells and development of the murine intraretinal microglial network: An in vivo study using fluorescent dyes. Glia 32, 91–101.3.0.CO;2-X>CrossRefGoogle Scholar
Cai, S., Therattil, A. & Vajzovic, L. (2020). Recent developments in pediatric retina. Current Opinion in Ophthalmology 31, 155–160.CrossRefGoogle ScholarPubMed
Caldeira, C., Oliveira, A.F., Cunha, C., Vaz, A.R., Falcao, A.S., Fernandes, A. & Brites, D. (2014). Microglia change from a reactive to an age-like phenotype with the time in culture. Frontiers in Cellular Neuroscience 8, 152.CrossRefGoogle Scholar
Chen, J., Stahl, A., Hellstrom, A. & Smith, L.E. (2011). Current update on retinopathy of prematurity: Screening and treatment. Current Opinion in Pediatrics 23, 173–178.CrossRefGoogle ScholarPubMed
Chu, X., Zhang, X., Gong, X., Zhou, H. & Cai, C. (2020). Effects of hyperoxia exposure on the expression of Nrf2 and heme oxygenase-1 in lung tissues of premature rats. Molecular and Cellular Probes 51, 101529.CrossRefGoogle ScholarPubMed
Chui, T.Y., Bissig, D., Berkowitz, B.A. & Akula, J.D. (2012). Refractive development in the “ROP Rat”. Journal of Ophthalmology 2012, 956705.CrossRefGoogle ScholarPubMed
Fischer, F., Martin, G. & Agostini, H.T. (2011). Activation of retinal microglia rather than microglial cell density correlates with retinal neovascularization in the mouse model of oxygen-induced retinopathy. Journal of Neuroinflammation 8, 120.CrossRefGoogle ScholarPubMed
Hansen, R.M., Moskowitz, A., Akula, J.D. & Fulton, A.B. (2017). The neural retina in retinopathy of prematurity. Progress in Retinal and Eye Research 56, 32–57.CrossRefGoogle ScholarPubMed
Hellstrom, A. & Hard, A.L. (2019). Screening and novel therapies for retinopathy of prematurity—a review. Early Human Development 138, 104846.CrossRefGoogle ScholarPubMed
Hellstrom, A., Smith, L.E. & Dammann, O. (2013). Retinopathy of prematurity. Lancet 382, 1445–1457.CrossRefGoogle ScholarPubMed
Higgins, R.D. (2019). Oxygen saturation and retinopathy of prematurity. Clinics in Perinatology 46, 593–599.CrossRefGoogle ScholarPubMed
Ivanova, E., Toychiev, A.H., Yee, C.W. & Sagdullaev, B.T. (2013). Optimized protocol for retinal wholemount preparation for imaging and immunohistochemistry. Journal of Visualized Experiments 82, e51018.Google Scholar
Jalali, S., Azad, R., Trehan, H.S., Dogra, M.R., Gopal, L. & Narendran, V. (2010). Technical aspects of laser treatment for acute retinopathy of prematurity under topical anesthesia. Indian Journal of Ophthalmology 58, 509–515.CrossRefGoogle ScholarPubMed
Kahroba, H. & Davatgaran-Taghipour, Y. (2020). Exosomal Nrf2: From anti-oxidant and anti-inflammation response to wound healing and tissue regeneration in aged-related diseases. Biochimie 171–172, 103–109.CrossRefGoogle ScholarPubMed
Kataoka, K., Nishiguchi, K.M., Kaneko, H., van Rooijen, N., Kachi, S. & Terasaki, H. (2011). The roles of vitreal macrophages and circulating leukocytes in retinal neovascularization. Investigative Ophthalmology & Visual Science 52, 1431–1438.CrossRefGoogle ScholarPubMed
Kopacz, A., Kloska, D., Forman, H.J., Jozkowicz, A. & Grochot-Przeczek, A. (2020). Beyond repression of Nrf2: An update on Keap1. Free Radical Biology and Medicine 157, 63–74.CrossRefGoogle ScholarPubMed
Li, B., Nasser, M.I., Masood, M., Adlat, S., Huang, Y., Yang, B., Luo, C. & Jiang, N. (2020). Efficiency of traditional Chinese medicine targeting the Nrf2/HO-1 signaling pathway. Biomedicine & Pharmacotherapy 126, 110074.CrossRefGoogle ScholarPubMed
Madden, S.K. & Itzhaki, L.S. (2020). Structural and mechanistic insights into the Keap1-Nrf2 system as a route to drug discovery. Biochimica et Biophysica Acta Proteins and Proteomics 1868, 140405.CrossRefGoogle ScholarPubMed
Ren, D., Villeneuve, N.F., Jiang, T., Wu, T., Lau, A., Toppin, H.A. & Zhang, D.D. (2011). Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proceedings of the National Academy of Sciences of the United States of America 108, 1433–1438.CrossRefGoogle ScholarPubMed
Sen, P., Wu, W.C., Chandra, P., Vinekar, A., Manchegowda, P.T. & Bhende, P. (2020). Retinopathy of prematurity treatment: Asian perspectives. Eye (London) 34, 632–642.CrossRefGoogle ScholarPubMed
Turpaev, K., Krizhanovskii, C., Wang, X., Sargsyan, E., Bergsten, P. & Welsh, N. (2019). The protein synthesis inhibitor brusatol normalizes high-fat diet-induced glucose intolerance in male C57BL/6 mice: Role of translation factor eIF5A hypusination. The FASEB Journal 33, 3510–3522.CrossRefGoogle ScholarPubMed
Uno, K., Prow, T.W., Bhutto, I.A., Yerrapureddy, A., McLeod, D.S., Yamamoto, M., Reddy, S.P. & Lutty, G.A. (2010). Role of Nrf2 in retinal vascular development and the vaso-obliterative phase of oxygen-induced retinopathy. Experimental Eye Research 90, 493–500.CrossRefGoogle ScholarPubMed
Supplementary material: PDF

Liang and Wang supplementary material

Liang and Wang supplementary material

Download Liang and Wang supplementary material(PDF)
PDF 83 KB